Sutent Adjunctive Treatment of Differentiated Thyroid Cancer.

Trial Profile

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer.

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Sunitinib (Primary) ; Iodine radioactive
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms IIT Sutent
  • Most Recent Events

    • 24 Mar 2016 Status changed from active, no longer recruiting to completed, according to record.
    • 28 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by
    • 12 Mar 2014 Planned number of patients changed from 46 to 35 as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top